WO2006072152A2 - Suppresseur de lymphocytes b autoreactifs associes a des maladies - Google Patents

Suppresseur de lymphocytes b autoreactifs associes a des maladies Download PDF

Info

Publication number
WO2006072152A2
WO2006072152A2 PCT/BG2006/000001 BG2006000001W WO2006072152A2 WO 2006072152 A2 WO2006072152 A2 WO 2006072152A2 BG 2006000001 W BG2006000001 W BG 2006000001W WO 2006072152 A2 WO2006072152 A2 WO 2006072152A2
Authority
WO
WIPO (PCT)
Prior art keywords
immunoglobulin
disease
suppressor
affinity
suppressor according
Prior art date
Application number
PCT/BG2006/000001
Other languages
English (en)
Other versions
WO2006072152A3 (fr
Inventor
Tchavdar Vassilev
Andrei Tchorbanov
Original Assignee
Tchavdar Vassilev
Andrei Tchorbanov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tchavdar Vassilev, Andrei Tchorbanov filed Critical Tchavdar Vassilev
Priority to EP06703172A priority Critical patent/EP1844075A2/fr
Publication of WO2006072152A2 publication Critical patent/WO2006072152A2/fr
Publication of WO2006072152A3 publication Critical patent/WO2006072152A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Definitions

  • the invention relates to a suppressor of disease-associated autoreactive B lymphocytes in autoimmune disorders with three different ligands incorporated into one single molecule and manifesting affinity to one activating and to two inhibiting B cell receptors.
  • autoimmune diseases develop in approximately two percent of the human population. In these pathological states, the patients' own tissues and organs are attacked by the immune system by autoantibodies or by autoreactive T lymphocytes. Serious damage or destruction of the targeted tissue results from the autoimmune attack. Depending on the number of organs targeted, autoimmune diseases are divided into two groups - systemic and organ-specific. The anti-inflammatory and immunosuppressive drugs used presently to treat them in most cases diminish or delay the injury to the targeted tissue, but do not affect the primary disease itself. Even more, such medicines have serious and even life-threatening side-effects.
  • the synthetic DWEYSVWLSN peptide is shown to mimic antigenically native (double stranded) DNA and to be bound by disease-associated anti-DNA antibodies [Putterman, C. et al. (2000), J Immunol 164,2542].
  • Patent application PCT/BG04/00010A1 describes an agent for selective suppression of disease-associated B-lymphocytes, the agent being a chimeric antibody molecule that cross-links the B cell immunoglobulin receptors with preselected anti-self specificity with the inhibitory Fc ⁇ RllB receptors.
  • This agent is active only on IgG receptor-expressing B lymphocytes.
  • WO03/030835A3 relates to a method for designing bispecific antibodies for regulating immune responses, wherein said bispecific antibodies bind to one activating and to one inhibiting receptor. As one of the possible inhibiting receptors Fc ⁇ RIIB is chosen. CD22 is not mentioned.
  • the bispecific antibodies according to the above cited document, are only active if administered with an agent that stimulates the expression of an inhibiting receptor or one activating receptor or with additional therapeutics.
  • WO9707218 describes a fusion protein that cross-links activating antigen- specific receptors with inhibiting receptors on targeted B cells.
  • this fusion protein binds only to the human Fc ⁇ RIIB (CD32) and targets only B cells with IgG, but not these with immunoglobulin M antigen receptors [Wakabayashi, C. et al. (2002), Science 298,2392].
  • the invention relates to a suppressor of disease-associated autoreactive B lymphocytes with affinity to inhibitory B-lymphocyte receptors possessing three different ligands, incorporated into one single molecule.
  • the suppressor possesses affinity to one activating receptor and to two inhibiting B cell receptors and is build of an immunoglobulin G backbone and of two synthetic components.
  • the first of the three ligands is a part of the immunoglobulin G backbone and the second and third ligands are the two synthetic components ( Figure 1).
  • the first synthetic component coupled to the immunoglobulin G backbone, is a peptide epitope with affinity to the activating immunoglobulin receptors on targeted autoreactive B cells. It is a DNA-mimotope peptide made of ten aminoacids - DWEYSVWLSN (SEQ ID NO.1), where a hexamethylene linker is added to the C-end of the peptide.
  • the second synthetic component coupled to the immunoglobulin G backbone is a synthetic peptide GGPGG (SEQ ID NO. 2) with a hexamethylene group at its C-end.
  • a STN epitope with a free terminal 2,6 sialic acid is coupled to the N-end of the peptide ( Figure 2).
  • an immunoglobulin G backbone a mouse monoclonal IgG antibody is used. It is obtained from IP 2-11-1 hybridoma cells grown in protein-free CHO medium. The immunoglobulin fraction of the synthetic medium is isolated after the end of the cultivation by ammonium sulfate precipitation and subsequent dialysis against phosphate-buffered saline pH 7.2.
  • the monoclonal IgG antibody is coupled to the modified DWEYSVWLS N and to the STN-containing peptides using 1-ethyl- 3(3'-dimethylaminopropyl) carboimidine.HCI (EDC) [Bauminger, S. et al. (1980) Methods in Enzymology. 70,151].
  • the components for the construction of the trispecific immunoglobulin molecule are prepared as follows. A 1.5 mg/ml solution of the monoclonal IgG in phosphate buffer pH 6.0, 0.3 mg/ml solution of EDC in PBS pH 6.0 and 0.2 mg/ml solutions of both peptides in dimethylphormamide/ phosphate (ratio of 1 :9) buffer are made. 7.5 ml of the mixed peptide solution is added to 3.75 ml EDC and to 10 ml of the IgG solution, the volume is brought to 150 ml with phosphate buffered saline pH 6.0. The mixture is incubated for 16 hours at +4 0 C with constant stirring.
  • This preparation contains the trispecific immunoglobulin molecules, composed of the monoclonal IgG backbone, the modified CD22- binding STN epitope and the DNA-mimicking DWEYSVWLSN peptide.
  • the protein content of chimera solution is determined spectrophotometrically at 280 nm.
  • the purity of the constructed chimera is analyzed by SDS-PAGE under non-reducing conditions.
  • the ability of the trispecific immunoglobulin molecule according to the invention to engage the CD22 and Fc ⁇ Rllb inhibitory receptors and to suppress selectively pathological DNA-specific B lymphocytes with IgM and with IgG antigen receptors is analyzed in vivo in animals that develop spontaneously an autoimmune disease, namely systemic lupus erythematosus.
  • the study showed that the trispecific immunoglobulin molecule bound the inhibitory receptors on targeted disease-associated DNA-specific B cells and suppressed the activity of the latter.
  • the healthy animals do not excrete proteins with the urine. Proteinuria levels correlate with the severity of renal involvement in lupus.
  • the administration of the trispecific immunoglobulin molecule according to the invention resulted in the suppression of the IgM and IgG anti-DNA antibody levels, of proteinuria and in the increased survival time of the animals ( Figures 3-5).
  • Figure 1 shows a schematic drawing of the trispecific immunoglobulin molecule, according to the invention.
  • the DNA-mimicking and the STN epitopes are coupled to an IgG backbone.
  • Figure 2 represents a scheme of the constructed modified STN epitope.
  • Figure 3 shows the effect of the trispecific immunoglobulin molecule according to the invention on the levels of anti-DNA antibodies in treated lupus-prone MRL/lpr mice.
  • Figure 4 shows the effect of trispecific immunoglobulin molecule, according to the invention on albuminuria levels in treated MRL/lpr mice (* p ⁇ 0.05; **p ⁇ 0.01 and ***p ⁇ 0.001 relative to controls, unpaired f-test).
  • Figure 5 proves that the administration of the trispecific immunoglobulin molecule, according to the invention increases survival in female lupus- prone MLR/lpr mice (*p ⁇ 0.05 relative to controls, unpaired f-test).
  • a decapeptide DWEYSVWLSN (SEQ ID NO. 1), that mimics antigenically DNA, was also coupled to the IgG backbone.
  • a hexamethylene group was also added to the C-end of this peptide.
  • Example 2 Construction of the chimeric immunoglobulin molecule.
  • a 1.5 mg/ml solution of the monoclonal IgG in phosphate buffer pH 6.0, 0.3 mg/ml solution of EDC in PBS pH 6.0 and 0.2 mg/ml solutions of both peptides in dimethylphormamide/ phosphate (ratio of 1 :9) buffer are made.
  • 7.5 ml of the mixed peptide solution is added to 3.75 ml EDC and to 10 ml of the IgG solution, the volume is brought to 150 ml with phosphate buffered saline pH 6.0. The mixture is incubated for 16 hours at +4 0 C with constant stirring.
  • This preparation contains the trispecific immunoglobulin molecules, composed of the monoclonal IgG backbone, the modified CD22-binding STN epitope and the DNA-mimicking DWEYSVWLSN peptide. ( Figure 1).
  • the protein content of the solution is determined spectrometrically at 280 nm.
  • the purity of the constructed chimeric antibody is determined by SDS- PAGE under non-reducing conditions.
  • Example 3 Determinantion of the effect of the administration of the chimeric antibody in autoimmune animals, in particular in lupus-prone mice.
  • the constructed trispecific immunoglobulin molecule has been administered intravenously twice weekly (20 ug/dose) to groups of ten 7- and of 18-weeks old female MRL/lpr mice. Control group have been injected with the same amount of a similar modified antibody molecule that lacked the STN epitope and another control groups have been treated with PBS alone. It is known that female mice from this strain spontaneously develop at the age of 7-9 weeks a lupus-like disease accompanied by the appearance of high levels of disease-associated anti-double stranded DNA antibodies. These levels have been significantly reduced in the group treated with the trispecific immunoglobulin molecule, according to the invention ( Figure 3).
  • the lupus glomerulonephritis results in kidney failure that is a major cause for the death of the animals.
  • the quantity of proteins in the urine a measure of the severity of kidney disease, has been determined by using a standard dry strip test (from Bayer, UK).
  • the administration of the trispecific immunoglobulin molecule according to the invention delays the increase of albuminuria that is seen in the control animals (Figure 4).
  • the treated mice survive significantly longer than the control ones ( Figure 5).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un suppresseur de lymphocytes B autoréactfs associés à des maladies, présentant une affinité pour trois récepteurs de lymphocyte B différents. Ledit suppresseur, qui est constitué d'une ossature d'immunoglobuline G et de deux composants synthétiques, est conçu pour être utilisé dans le traitement de troubles auto-immuns.
PCT/BG2006/000001 2005-01-05 2006-01-04 Suppresseur de lymphocytes b autoreactifs associes a des maladies WO2006072152A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06703172A EP1844075A2 (fr) 2005-01-05 2006-01-04 Suppresseur de lymphocytes b autoreactifs associes a des maladies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BG109003A BG65954B1 (bg) 2005-01-05 2005-01-05 Средство за селективно подтискане активността на патологични автореактивни в-клетки
BG109003 2005-01-05

Publications (2)

Publication Number Publication Date
WO2006072152A2 true WO2006072152A2 (fr) 2006-07-13
WO2006072152A3 WO2006072152A3 (fr) 2008-12-24

Family

ID=36647833

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BG2006/000001 WO2006072152A2 (fr) 2005-01-05 2006-01-04 Suppresseur de lymphocytes b autoreactifs associes a des maladies

Country Status (3)

Country Link
EP (1) EP1844075A2 (fr)
BG (1) BG65954B1 (fr)
WO (1) WO2006072152A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015184203A1 (fr) 2014-05-29 2015-12-03 Macrogenics, Inc. Molécules de liaison trispécifiques et leurs procédés d'utilisation
WO2018175993A1 (fr) * 2017-03-24 2018-09-27 Orpheus Bioscience Inc. Pantids pour le traitement de troubles auto-immuns
US11174315B2 (en) 2015-10-08 2021-11-16 Macrogenics, Inc. Combination therapy for the treatment of cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997007218A1 (fr) * 1995-08-16 1997-02-27 Novartis Ag Proteines de fusion entre cd32 et des allergenes
US6001964A (en) * 1995-09-20 1999-12-14 Albert Einstein College Of Medicine Of Yeshiva University Peptides which bind to anti-double stranded DNA antibody
US20010053770A1 (en) * 1998-11-17 2001-12-20 David Thomas Bispecific molecules cross-linking ITIM and ITAM for therapy
WO2003030835A2 (fr) * 2001-10-12 2003-04-17 Schering Corporation Utilisation d'anticorps bispecifiques pour reguler des reponses immunitaires
WO2005023871A1 (fr) * 2003-09-04 2005-03-17 Ministry Of Education And Science Agent pour la suppression selective de lymphocytes b autoreactifs associes a la maladie

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997007218A1 (fr) * 1995-08-16 1997-02-27 Novartis Ag Proteines de fusion entre cd32 et des allergenes
US6001964A (en) * 1995-09-20 1999-12-14 Albert Einstein College Of Medicine Of Yeshiva University Peptides which bind to anti-double stranded DNA antibody
US20010053770A1 (en) * 1998-11-17 2001-12-20 David Thomas Bispecific molecules cross-linking ITIM and ITAM for therapy
WO2003030835A2 (fr) * 2001-10-12 2003-04-17 Schering Corporation Utilisation d'anticorps bispecifiques pour reguler des reponses immunitaires
WO2005023871A1 (fr) * 2003-09-04 2005-03-17 Ministry Of Education And Science Agent pour la suppression selective de lymphocytes b autoreactifs associes a la maladie

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CAMBIER J C: "INHIBITORY RECEPTORS ABOUND?" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 94, no. 12, 10 June 1997 (1997-06-10), pages 5993-5995, XP002061987 ISSN: 0027-8424 *
DIJSTELBLOEM H M ET AL: "Inflammation in autoimmunity: receptors for IgG revisited" TRENDS IN IMMUNOLOGY, ELSEVIER, RAHWAY, NJ, US, vol. 22, no. 9, 1 September 2001 (2001-09-01), pages 510-516, XP004301119 ISSN: 1471-4906 *
LANOUE ASTRID ET AL: "Interaction of CD22 with alpha2,6-linked sialoglycoconjugates: Innate recognition of self to dampen B cell autoreactivity?" EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 32, no. 2, February 2002 (2002-02), pages 348-355, XP002395177 ISSN: 0014-2980 *
RUDGE ELIZABETH U ET AL: "Interleukin 4 reduces expression of inhibitory receptors on B cells and abolishes CD22 and FcgammaRII-mediated B cell suppression" JOURNAL OF EXPERIMENTAL MEDICINE, vol. 195, no. 8, 15 April 2002 (2002-04-15), pages 1079-1085, XP002395176 ISSN: 0022-1007 *
WELLMANN UTE ET AL: "Altered selection processes of B lymphocytes in autoimmune NZB/W mice, despite intact central tolerance against DNA" EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 31, no. 9, September 2001 (2001-09), pages 2800-2810, XP002395178 ISSN: 0014-2980 *
YUASA T ET AL: "DELETION OF FCGAMMA RECEPTOR IIB RENDERS H-2B MICE SUSCEPTIBLE TO COLLAGEN-INDUCED ARTHRITIS" JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 189, no. 1, 4 January 1999 (1999-01-04), pages 187-194, XP002932700 ISSN: 0022-1007 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015184203A1 (fr) 2014-05-29 2015-12-03 Macrogenics, Inc. Molécules de liaison trispécifiques et leurs procédés d'utilisation
US10633440B2 (en) 2014-05-29 2020-04-28 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules that specifically bind to multiple cancer antigens
US10647768B2 (en) 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
EP3954703A2 (fr) 2014-05-29 2022-02-16 MacroGenics, Inc. Molécules de liaison trispécifiques et leurs procédés d'utilisation
US11697684B2 (en) 2014-05-29 2023-07-11 Macrogenics, Inc. Tri-specific binding molecules that specifically bind to multiple cancer antigens
US11820818B2 (en) 2014-05-29 2023-11-21 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
US11174315B2 (en) 2015-10-08 2021-11-16 Macrogenics, Inc. Combination therapy for the treatment of cancer
WO2018175993A1 (fr) * 2017-03-24 2018-09-27 Orpheus Bioscience Inc. Pantids pour le traitement de troubles auto-immuns

Also Published As

Publication number Publication date
BG109003A (en) 2006-07-31
WO2006072152A3 (fr) 2008-12-24
BG65954B1 (bg) 2010-07-30
EP1844075A2 (fr) 2007-10-17

Similar Documents

Publication Publication Date Title
Monteiro et al. IgA fc receptors
US6660266B1 (en) Reversal of proinflammatory response by ligating the macrophage FcγRI receptor
Mkaddem et al. IgA, IgA receptors, and their anti-inflammatory properties
JP6225142B2 (ja) 規則的に多量体化された免疫グロブリンＦｃ組成物を作製するための天然ヒトタンパク質断片の融合タンパク質
CA2146647C (fr) Traitement d'affections auto-immunes et inflammatoires
US5958409A (en) Method for treating multiple sclerosis
de Ståhl et al. A role for complement in feedback enhancement of antibody responses by IgG3
SK7322001A3 (en) Remedies for immunological diseases
NO320354B1 (no) Anvendelse av et CD40-bindende protein som har evne til a binde CD40 og hindrer binding av CD40 til CD40-L ved fremstilling av et middel for forebyggelse eller behandling av en neoplasmatisk sykdom.
EP0914347A2 (fr) Proteine de fusion d'un peptide de complexe majeur d'histocompatibilite multivalent permettant la modulation de fonction specifiques de lymphocytes t
JPH05507197A (ja) 結合部位を含む可溶性ペプチド類縁体
JP4307743B2 (ja) 敗血症療法のための免疫吸着剤
Giorgini et al. FcγRIII and FcγRIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies
KR19990036440A (ko) 알러젠-ｘｃｄ３２융합 단백질
WO2006072152A2 (fr) Suppresseur de lymphocytes b autoreactifs associes a des maladies
Tchorbanov et al. Selective silencing of DNA‐specific B lymphocytes delays lupus activity in MRL/lpr mice
CN101522714A (zh) 用于治疗过敏性疾病的IgE重定位、功能性改变分子（ERFAM）
Chowers et al. Efficacy of anti-TNF in Crohn's disease: how does it work?
Pugin Recognition of bacteria and bacterial products by host immune cells in sepsis
Gustavsson et al. Low responsiveness to immunization with immunoglobulin E/antigen and immunoglobulin G/antigen complexes in H‐2Ab mice
Dimitrova et al. Target silencing of disease-associated B-lymphocytes by chimeric molecules in SCID model of pristane-induced autoimmunity
Nigrovic et al. Mast cells in autoantibody responses and arthritis
WO1999047166A1 (fr) FRAGMENTS IMMUNOMODULATEURS DE GLOBULINES ANTILYMPHOCYTAIRES POLYCLONALES (ALGs) ET UTILISATIONS ASSOCIEES
Van de Velde et al. Native soluble CD5 delivers a costimulatory signal to resting human B lymphocytes
Wakayama et al. IgG-mediated anaphylaxis via Fcγ receptor in CD40-deficient mice

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006703172

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006703172

Country of ref document: EP